Company Overview
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.11.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -11.35% |
| 6 Months: | +27.86% |
| 3 Months: | +34.76% |
| 1 Month: | +21.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 41.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACET Adicet Bio, Inc. PHARMA | 9.73 | -0.93 | $91.09M | 0.00% | -71.49% | -78.08% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.89M | 32.39M | 27.95M | 31.89M | 21.57M | - |
| Operating Income | -3.36M | -4.06M | -3.94M | -7.52M | -10.20M | -14.11M | -9.03M | -6.36M | -11.69M | -19.17M | -15.22M | -29.44M | -7.56M | -8.63M | -13.65M | -21.35M | -10.83M | -13.71M | 4.71M | -22.71M | -22.98M | -33.32M | -34.89M | -52.26M | -30.87M | -32.85M | -33.15M | - | -29.89M | -32.39M | -27.95M | -31.89M | -21.57M | -22.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.53M | -29.56M | -25.27M | -29.02M | -18.88M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 12.00K | 24.00K | 23.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.21M | -31.22M | -26.86M | -30.52M | -20.24M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -3.36M | -4.06M | -3.31M | -23.05M | -9.86M | -13.59M | -8.41M | -5.76M | -4.13M | -2.65M | -14.78M | -28.89M | -4.49M | -8.46M | -14.78M | -21.32M | -10.85M | -14.01M | 4.62M | -22.54M | -22.00M | -30.88M | -32.40M | -49.88M | -28.02M | -29.90M | -30.48M | - | -28.21M | -31.22M | -26.86M | -30.52M | -20.24M | -21.36M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.82 | -0.34 | -0.44 | 0.10 | -0.56 | -0.53 | -0.72 | -0.75 | -1.16 | -0.35 | -0.33 | -0.34 | - | -4.96 | -5.44 | -4.64 | -2.94 | -1.88 | -1.99 |
| R&D Expense | 3.29M | 3.42M | 3.33M | - | 8.11M | 11.85M | 6.76M | - | 8.85M | 16.55M | 6.33M | - | 7.03M | 8.68M | 8.94M | 11.74M | 10.62M | 11.93M | 13.48M | 16.18M | 16.57M | 26.76M | 28.36M | 26.17M | 23.90M | 25.90M | 26.25M | - | 22.81M | 28.42M | 22.85M | - | 17.49M | 18.45M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 24.99M | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 97.54M | 132.58M | 127.61M | 122.11M |
| Operating Income | -18.88M | -14.96M | -31.39M | -39.19M | -61.43M | -72.55M | -132.58M | -127.61M | -122.11M |
| EBITDA | - | - | - | - | - | -67.14M | -136.53M | -110.65M | -110.39M |
| Interest Expense | - | - | - | - | - | 80.00K | 25.00K | 4.00K | 36.00K |
| Pretax Income | - | - | - | - | - | -69.79M | -142.66M | -117.12M | -116.80M |
| Tax Provision | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -33.78M | -9.30M | -28.14M | -36.68M | -62.00M | -69.79M | -142.66M | -117.12M | -116.80M |
| Diluted EPS | - | - | - | - | -2.00 | -27.20 | -52.96 | -21.28 | -16.95 |
| R&D Expense | 16.84M | 14.72M | 23.69M | 34.33M | 48.94M | 71.25M | 106.04M | 99.32M | 99.13M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 55.19M | 109.94M | 81.59M | 153.84M | - | 330.69M | 207.29M | 220.22M | 192.35M |
| Current Assets | - | - | - | - | - | - | - | 261.04M | 162.27M | 180.14M | 160.93M |
| Cash & Equivalents | 0 | 0 | 53.35M | 9.47M | 10.61M | 84.33M | - | 257.66M | 159.71M | 56.49M | 38.92M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 185.00K | 0 | - | - | - |
| Total Liabilities | - | - | 5.50M | 5.74M | 27.87M | 44.01M | - | 38.35M | 37.12M | 33.61M | 33.15M |
| Current Liabilities | - | - | 5.50M | 5.72M | 14.87M | 22.48M | - | 19.71M | 19.29M | 19.39M | 21.53M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 21.02M | 20.92M | 17.23M | 14.74M |
| Total Equity | 0 | 0 | -26.95M | -33.52M | -60.37M | 109.83M | - | 292.34M | 170.18M | 186.61M | 159.21M |
| Shares Outstanding | - | - | - | - | - | - | - | 2.68M | 2.70M | 5.16M | 9.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.98M | -18.18M | -27.88M | -41.55M | - | -44.77M | -93.72M | -92.38M | -95.25M |
| Investing Cash Flow | -44.00K | -16.06M | -47.93M | 115.22M | - | -16.78M | -4.46M | -119.24M | 2.39M |
| Financing Cash Flow | 64.38M | 11.05M | 76.94M | 303.00K | - | 41.51M | 236.00K | 111.31M | 75.25M |
| Capital Expenditure | -44.00K | -876.00K | -1.07M | -990.00K | - | -16.78M | -4.46M | -1.12M | -1.74M |
| Free Cash Flow | -11.03M | -19.06M | -28.95M | -42.54M | - | -61.55M | -98.18M | -93.50M | -96.98M |
| Net Change in Cash | - | - | - | - | - | -20.04M | -97.94M | -100.31M | -17.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -290.3% | - | - | - |
| Net Margin % | - | - | - | - | - | -279.3% | - | - | - |
| ROE % | 125.3% | 27.7% | 46.6% | -33.4% | - | -23.9% | -83.8% | -62.8% | -73.4% |
| ROCE % | -38.0% | -14.4% | -47.0% | -29.8% | - | -23.3% | -70.5% | -63.5% | -71.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 9.96% | 932.62K | $8.56M |
| 2 | Orbimed Advisors LLC. | 9.02% | 844.79K | $7.76M |
| 3 | Franklin Resources, Inc. | 6.69% | 626.57K | $5.75M |
| 4 | Citadel Advisors Llc | 4.62% | 432.74K | $3.97M |
| 5 | Vanguard Capital Management LLC | 3.67% | 343.23K | $3.15M |
| 6 | Adage Capital Partners GP L.L.C. | 2.93% | 274.38K | $2.52M |
| 7 | Renaissance Technologies, LLC | 2.84% | 265.94K | $2.44M |
| 8 | Stonepine Capital Management, LLC | 2.62% | 245.52K | $2.25M |
| 9 | Alyeska Investment Group, L.p. | 2.18% | 203.80K | $1.87M |
| 10 | Schonfeld Strategic Advisors Llc | 2.09% | 195.51K | $1.79M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACET
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisi…
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
REDWOOD CITY, Calif., September 02, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic …
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., August 31, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic mal…
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
REDWOOD CITY, Calif., August 27, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic mal…
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
ACET — Frequently Asked Questions
What is the current share price of Adicet Bio, Inc. (ACET)?
As of 2026-09-19 21:16 PDT, Adicet Bio, Inc. (ACET) trades at $9.73 on NasdaqCM. Its 52-week range is $6.11 to $16.64.
What is the market capitalisation of ACET?
Adicet Bio, Inc. (ACET) has a market capitalisation of $91.09M on NasdaqCM.
What is the P/E ratio of ACET?
ACET trades at a trailing price-to-earnings (P/E) ratio of -0.93. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.85.
What is the return on equity (ROE) of ACET?
ACET has a return on equity (ROE) of -78.08%. Its return on capital employed (ROCE) is -71.49%.
Is ACET a good stock to buy?
This page provides a data-driven analysis of Adicet Bio, Inc. (ACET), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.